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Abstract
Background: Adjuvant Radiotherapy (RT) after surgical removal of tumors proved beneficial in
long-term tumor control and treatment planning. For many years, it has been well concluded that
radio-sensitivities of tumors upon radiotherapy decrease according to the sizes of tumors and RT
models based on Poisson statistics have been used extensively to validate clinical data.
Results: We found that Poisson statistics on RT is actually derived from bacterial cells despite of
many validations from clinical data. However cancerous cells do have abnormal cellular
communications and use chemical messengers to signal both surrounding normal and cancerous
cells to develop new blood vessels and to invade, to metastasis and to overcome intercellular
spatial confinements in general. We therefore investigated the cell killing effects on adjuvant RT and
found that radio-sensitivity is actually not a monotonic function of volume as it was believed before.
We present detailed analysis and explanation to justify above statement. Based on EUD, we present
an equivalent radio-sensitivity model.
Conclusion: We conclude that radio sensitivity is a sophisticated function over tumor volumes,
since tumor responses upon radio therapy also depend on cellular communications.
Background
Radiotherapy (RT) and surgery are proven methods of
treating cancer patients. RT plays an important roles in
long-term control of tumors and has been combined with
surgery or chemotherapy in addition to its role as a stand-
alone therapy.
Tumor responses to RT have been observed by using the
cell-sorter protocol [1,2]. Clinical observations are often
based on visualizations of tumor lumps using medical
imaging. However, for microscopic disease [3,4]; tumors
are invisible to modern imaging technologies. Many cell-
killing models have been developed and have been
extended to microscopic disease [3]. Linear quadratic
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models based on Poisson statistics have been developed
to fit clinical observations [5]. Adjuvant RT [6,7] follow-
ing surgery has been widely used in many treatment plans.
The assumption behind adjuvant RT is that microscopic
amounts of tumor tissue may remain after surgery; these
must be destroyed to prevent tumor recurrence. Despite
extensive studies of tumor controls and the biological
effects of RT, little is known about the mechanism of RT
than what is thought to be known [8], especially for
microscopic disease, due to the limitations of current in-
vivo and in-vitro experimental methods.
We found that radio-sensitivity is not a monotonic func-
tion over tumor volumes especially for microscopic dis-
ease and we show that Poisson statistics-based models can
fit clinical data despite that they are wrongly based on the
biological behaviors of bacterial cells. We showed that
large fluctuations on radio-sensitivity over tumor volumes
may not matter clinically, thus validates any Poisson
models using cell killing effects over tumor volumes. This
also justifies the equivalent radio-sensitivity model on RT.
We consider that a tumor cell is a mammalian cell that is
not a self-independent complete life organism but a bac-
terial cell is. A normal mammalian cell differentiates, has
limited proliferation, has spatial arrangement, maintain-
ing a healthy cell communication, and would not be rec-
ognized by mammalian immune system as alien, while a
tumor cell may not differentiates, may proliferates indefi-
nitely, does not have regular spatial arrangement, has
malfunctioning cell communication, and may be recog-
nized by the immune system (especially for virus infected
cancers). Therefore, we should investigate the effect of RT
on tumor cells, with considerations of cellular communi-
cations and signaling transductions.
Methods
Poisson statistics and cell killing
RT models based on Poisson statistics are supported by
clinical data and have become widely accepted for the past
half centaury. According to the Poisson model [5,9,10],
the probability that a cell receives m lethal events is:
P(Y, m) = Yme-Y/m!                                                          (1)
where Y is the rate of lethal events.
In RT, a cell survives on radiation only if it receives zero
lethal events, corresponding to m = 0 in (1). The probabil-
ity that a cell survives on radiation is therefore:
P(Y, m = 0) = e-Y
For a linear model, Y is proportional to the dose D, with
coefficient α. For a linear quadratic model, Y is not only
proportion to the dose but also depends on a quadratic
function of the dose D with an additional coefficient β. In
addition, cell growth occurs between RT treatments; it is
assumed that cell proliferation is proportional to the time
t between treatments, with another additional coefficient
λ. Then the rate of lethal events is:
Y = α D + β Dd - λ t                                                       (2)
where D is the total dose and d is the dose per RT treat-
ment, so that D = d f, where f is the number of treatments.
The survival fraction of the cells is:
S = e-Y                                                                             (3)
Assuming there are N tumor cells before RT, the Tumor
Control Probability (TCP) is given as:
It is well known that dose in-homogeneity [3,8-10] has
always been an issue in RT models; it turns out that if D(x)
is actually a distribution function of space, then both RT
and medical image models become mathematically
intractable in many situations. Owning to the remarkable
discovery of equivalent uniform dose (EUD) model [9],
much of the intractable situations have been solved. For
any RT or diagnostic radiation, there exists an equivalent
uniform dose that achieves the same clinical result even
though the actual dose is not uniform. Niemierko's EUD
[9] has been proved correct and effective in RT and diag-
nostic image models. Therefore, we can use an equivalent
uniform distributed dose per fraction in RT regardless the
nonuniform dose. In this way the total dose is approxi-
mately a discrete function linearly proportional to the
time after the start of RT [10]. The cell repopulation con-
stant can be scaled [10] by the number of days or hours
per fraction, then
λ' = λ d t/f                                                                       (5)
Therefore, the Tumor Control Probability (TCP) is given
as:
where
α' = α + β d - λ'                                                             (7)
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The Poisson statistics – widely validated models were 
actually based on bacterial cells
We investigate the biological behaviors of bacterial cells
and found that the widely validated Poisson-statistics
based RT models were actually based on the bacterial cells
rather than human cancerous cells, because those RT
models all assumed no cellular communications.
It has been studied for many years that bacterial popula-
tion is an exponential growth upon available simple
energy source (i.e. light, carbon etc). This because bacte-
rial cells do not communication each other and each cell
is an independent complete living organism. Models for
bacterial cell growth have been developed and we find it
coincides with the RT models based on Poisson statistics.
Bacterial cell repopulation is exponentially growth subject
to the following differential equation:
dN/dt = λ N                                                                   (8)
In a RT model, the time required to double the amount of
cells is called clinical doubling time (CDT) [6] and is an
analogue of doubling the bacterial population.
Let N = 2No, from equation (8), then
CDT = log2/eλt                                                              (9)
λ = log2/CDT                                                              (10)
where log is the natural logarithm. In RT, CDT is usually a
clinically determined parameter. If λ is negative in equa-
tion (8), then λ is denoted as α, and is called radio-sensi-
tivity in RT, therefore equation (8) become:
dN/dt = -α d                                                                (11)
This equation indicates a log kill of cells on RT, which
coincides with Poisson statistics. For linear quadratic
model, cell killing is a function of the linear and quadratic
forms of dose and cell proliferation, therefore,
Y = α D + β Dd - λ t
The above equation coincides with equation (2) in RT
models based on Poisson statistics. Cell growth occurs
between each fractions of RT, so this effect must be coun-
teracted in the cell killing model. Therefore, Y is propor-
tional to dose and quadratic function of dose plus a
counter action from cell proliferation. TCP is then given
as:
This coincides with (4) in Poisson statistics.
The cell repopulation constant can be scaled by λ' = λ d t/
df. Then the "TCP" of equation for cell growth become:
where
α' = α + β d - λ'
This actually coincides with equation (6) in Poisson statis-
tics.
One may argue that we do not know if there is any inter-
cellular communication among bacterial cells. To answer
this, we need to look at metabolism and signal transduc-
tion of a bacterial cell. Bacterial reproduction and metab-
olism depend on simple energy source such as lights;
carbons rather advanced bio-organic compounds such as
sugar and protein supplies. A bacterial cell genome
encodes only a few thousands or even less protein-coding
genes (i.e. Haemophilus influenzae ~1740 genes and
Escherichia coli ~4400 genes) and there is no splicing or
alternative splicing in bacterial genome. Bacteria are
prokaryotes and even more advanced eukaryotes such as
budding yeast (Saccharomyces cerevisiae) containing only
6357 genes (among which ~5800 are functional) without
alternative splicing. But genes in a tumor cell are coded by
human genome and are abundant with splicing and alter-
native splicing, even though some genes may have been
mutated (virus induced cancer cells may contain virus
DNA sequences). None of bacterial genes code for com-
plex human transmembrane proteins with a least portions
of glycoprotein outside tumor cellular membrane for cel-
lular signaling and immune recognition. In fact, most bac-
terial cells have hard shells outside their cellular
membranes as protections, making that bacterial cells
unlikely communicate each others. Furthermore, a bacte-
rial cell does not have the complex signal transduction
like a tumor cell rather just simple expression of a few
genes such as HST (heat shock protein) upon changing
environments such as radiation exposure or heat. A bacte-
rial signal transduction does not have intercellular com-
munications and does not signaling immune
recognitions, which are the situations of tumor cells. But
the survival of mammalian cells including tumor cells
depend on intercellular communications, and sufficient
nutrients such as blood circulations, sugar, and protein
supplies as well as the expressions and regulations of a
number of human genes in a number of pathways, such as
apoptosis related pathways. Unfortunately, the widely
validated Poisson-statistics based models do not consider
the actual biological behaviors of tumor cells. Therefore,
we conclude that Poisson-statistics based models are actu-TCP e
Ne(-  D  d t= −
− +a b lDd )
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ally based on the biological behaviors of bacterial cells
rather than human cancerous cells. The biological mecha-
nisms of Poisson-statistics based RT models are wrong,
regardless that those RT models have been validated clin-
ically.
Calculation of tumour cell distribution upon RT
Since Poisson-statistics based RT models have been widely
proved correct clinically, we used breast cancer cumulative
Ipsilateral Breast Tumor Recurrence (IBTR) data in [6],
which is from five randomized control trials of lumpec-
tomy, with and without radio therapy in the early-stage
breast cancer in our investigations. CDT is a standard clin-
ical gauge to estimate the tumor development. For breast
cancer, the reported average CDT with small variation is
determined as 100 days [6], which is CDT = 100/365 in
the unit of year. Therefore, using equation (10), λ is deter-
mined as 2.3. At any time t, the new total number of cells
grown from the original cell number No is therefore given
by:
N = No*e2.3t                                                                 (12)
After surgery, if we know the remaining tumor cells, we
can estimate how long it will take to grow into a clinically
detectable tumor. Although distributions of the remain-
ing numbers of tumor cells right after surgical removal of
tumors are not known, they can be determined statisti-
cally from the year of tumor recurrence data as following:
We use the assumption that in general, observations of
tumor recurrence are referred as tumors sized around 1
centimeter in diameter, which corresponds to roughly 109
tumor cells [6,8]. Let us set Nc = 109 as a critical detectable
number of cells for a tumor detection. From (12) we get:
No = Nce-2.3Tc                                                                 (13)
where Tc is time for tumor recurrence to be observed after
surgery (i.e. Tc = 8 year). Equation (13) determines the
distribution of remaining tumor tissues right after surgery
from the available follow up tumor recurrence data
reported in [6].
Results
Fluctuations on radio sensitivities
Two sets of results based on the calculation using equa-
tion (13) have been obtained, one set refers RT after
lumpectomy and the other one is lumpectomy only. We
found the distribution of remaining tumor cells after sur-
gical removal of tumors without RT actually coincides
with an analytical form given below:
y(x) = a*(poisspdf(x, 2.2) + 3/4*poisspdf(x, 8))          (14)
where a = 23.659 and poisspdf (a standard Matlab ® func-
tion in statistics) is the probability mass (density) func-
tion of the Poisson distribution. The visualization of this
analytical form is shown in figure 1:
Equation (14) is validated by obtaining tumor recurrence
rates derived from equation (12). We then plot tumor
recurrence rates which are denoted as the red plot in the
figure 2. The curve represents the tumor recurrence rates as
a function of time (number of years after surgical removal
The combined Poisson distribution of remaining cells after surgeryFigure 1
The combined Poisson distribution of remaining cells after 
surgery. The x-axis represents cell numbers and y axis is the 
relative frequency.
Red line represents tumor re-occurrence rate without RT after surg ry while bl e line is the ate with RT after surgeryFigure 2
Red line represents tumor re-occurrence rate without RT 
after surgery while blue line is the rate with RT after surgery. 
IBTR (Ipsilateral Breast Tumor Recurrence) rate is shown in 
as purple diamond when a middle point value of the largest 
and the smaller cell killing rate was used; the rate is shown as 
green circle when largest cell killing rate was used.
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of tumor). From the plot, we can see that at the year 8, the
cumulative IBTR is 31%, which fits the data reported in
[6].
From tumor recurrence data, equation (13) gives the both
distributions of remaining of tumor cells after lumpec-
tomy with and without RT. By comparing two distribu-
tions, cell killing rates of RT on the remaining tumor
tissues after surgery are determined as the green line in fig-
ure 3.
In the figure 2, we also plot IBTR with radio therapy as
shown in the blue line. At year 8, IBTR is reduced from
31% without RT to 8% with RT, which matches exactly the
clinical observed statistics that was reported in [6].
This analysis shows that under the combined form of
Poisson distributions in (14), roughly 2/3 of patients do
not have a remaining tumor cell after the surgery and pre-
sumably no recurrence of tumor. Only about 1/3 of the
patients may have remaining microscopic tumors after
lumpectomy of breast cancer.
As visualized in Figure 3, it is observed that tumor tissues
of size 107 cells have largest cell killing rate on RT while 10
Remaining tumor cells after surgery gives the smallest cell
killing rate. It appears overall cell-killing rates varies sig-
nificantly according to tumor sizes for the microscopic
diseases but in general it shows a tendency that, the larger
the tumor size, the higher killing rate is. This is obviously
contradictory to current published literature and the com-
monly accepted conventions. Current RT models have
valid explanations on RT with a conclusion that the larger
the tumor is, the lesser cell killing rate is, due to larger
hypoxia effects on larger tumor upon RT. It might appear
that we have violated above proved conclusion on RT. We
would also actually correct because the conclusion should
not extend to microscopic diseases. An enormous issue
here is that would the large fluctuation on cell killing rates
affects the clinical outcome and would not matter some-
how? Otherwise either we or the RT models based on
Poisson-statistics are wrong! In the next sub-session we
show that our contradictory conclusion and the Poisson-
statistics based RT models can both fit clinically data well.
Clinically correct – biologically wrong models
We have shown that RT models using Poisson-statistics
are actually based on bacterial cells without considering
tumor cellular signaling. In this sub-session, we show that
the fluctuation on radio-sensitivity although significantly
varies may not matter too much in clinical outcomes.
Fluctuation can be smoothed by a combination of Pois-
son distributions as:
Kill = 3*(poisspdf(x, 3.5) + 2*poisspdf(x, 9))               (15)
Equation (15) is illustrated by the red curve in figure 3.
The green line represent original cell killing rates over the
tumor volumes. It shows radio-sensitivity is in general an
increasing function over tumor volumes for microscopic
diseases.
To test the validation of (15), we use equations (9) and
(12) to calculate the IBTR. We find it matches clinical data
very well and is also plotted as the blue line in figure 2. It
shows at year 8, the tumor recurrence rate is also accumu-
lated to 8% as reported in [6]. Therefore, the equation of
cell killing rate in (15), although coming with much less
fluctuation, is an increasing function of tumor volumes,
and does not affect much on the clinical outcomes.
In Poisson-statistics based RT models, constant radio sen-
sitivities are sometime used. We also investigate constant
radio sensitivities to validate the Poisson-statistics based
RT models. We can use a middle point value of the largest
and the smaller cell killing rate. The IBTR is then plotted
as the purple diamonds in figure 2. If we used the largest
cell killing rate, IBTR is plotted as green circle in figure 2.
Both situations give 8% of IBTR at the year 8. It is now can
be concluded that the large fluctuation of radio sensitivity
does not give obvious clinical difference. Using constant
radio-sensitivity in a tolerate range gives roughly same
clinical outcome. Therefore, a Poisson-statistics based
model using a constant radio-sensitivity can be correct
clinically.
Cell killing effects according to the tumor sizesFigure 3
Cell killing effects according to the tumor sizes. The green 
line represent original cell killing rates over the tumor vol-
umes, while the red line is killing rates over the tumor vol-
umns after smoothing by a combination of Poisson 
distributions.
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Comparing the two groups (with RT and without RT) of
IBTR data only gives us the total cell killing rates on the
completed RT. In real RT, dose is given by fractions. We
want to estimate the cell killing rates per fraction. Let us
assume the total dose is divided into just 10 fractions
(usually in real RT plan, there are more than 10 or even 20
fractions). From figure 3, we can see the largest cell killing
rate per fraction is less than 17% (if we use 20 fractions,
the cell killing rate per fraction is much smaller than 8%).
This largest killing rate corresponds to the microscopic
tumor tissue size of 107 tumor cells. This largest 17% is
significantly smaller than other reported in literatures
such as a popular 40% of cell killing rate per fraction. This
raises another contradiction.
A number of Poisson-statistics based RT models use the
concept of non-hitting cells upon radiation. If this is true;
and if we use 40% constant cell killing rate per fraction,
then the percentages of non-hitting cells are ranged
between 23% and 34% as plotted in figure 4. It appears
that tumor size of 10 cells receives largest hitting rate
while the non-hitting rate varies significantly over tumor
sizes. Such large variations violate the assumptions of
Poisson-statistics based RT models, which non-hitting
rate should be a constant over tumor volume. There is no
statistical reason why non-hitting rates should be fluctu-
ated so significantly over tumor volumes. We further
investigate the cell killing effects in the next section.
Since we use two set of IBTR data in [6], one is the tumor
recurrence with adjuvant RT, and the other one is no RT,
then we determine cell killing rates from cell distributions
by comparing the calculated results from RT and without
RT after surgery. We do not have to consider the quadratic
form or tumor proliferation explicitly as they have already
been included in equations (6) and (7). We have shown
that although cell killing rates vary significantly, Poisson-
statistics based RT models using constant radio sensitivity
can be correct. Now we can conclude that we can use an
equivalent uniform radio-sensitivity model that can be
clinically correct. The coefficient α' in equations (6) and
(7) can be considered as an equivalent radio-sensitivity,
because it can be used to achieve same clinical results
compared to more sophisticated linear – quadratic – pro-
liferation models, as far as there exists a dose that can be
considered uniform per fraction in RT. Even though uni-
form dose distribution can not be achieved clinically, we
still can use the simplified model as an equivalent to more
complicated models in the situations with quadratic form
and cell proliferation included. Because in real RT, dose
can never be absolutely uniform, however, Niemierko's
Equivalent Uniform Dose (EUD) [9] has solved the main
issues in RT. Non-uniform dose somehow may not affect
the radio sensitivity. We have shown a case that fluctua-
tion of radio-sensitivity does not matter in fitting clinical
data. As far as somehow equivalent uniformly distributed
dose is valid, equations (6) and (7) are valid. We name
this variant of RT model as an equivalent uniform radio
sensitivity model, as it utilizes a cornerstone in RT – the
Niemierko's EUD and other techniques [9,10]. The suc-
cesses of Niemierko's EUD in fitting clinical data also sup-
port the validation of the above equivalent uniform radio
sensitivity model.
Discussion
Clinically correct – biologically wrong models
We find that radio-sensitivity is proportional to tumor
size on microscopic diseases, which is evidently contradic-
tory to the common conclusions in RT models. We show
that a large fluctuation on radio-sensitivity may not mat-
ter and may give the same clinical outcome. We validate
the clinical correctness of RT models based on Poisson-
statistics using constant cell killing rates, regardless their
wrong biological mechanism that has been based on the
bacterial cells. This also validates the equivalent radio-
sensitivity model. Utilizing the concept of non-hitting
cells, many RT models have fitted the clinical data well. In
physics, de Broglie's wave-particle duality indicates any
radiation is also subject to Heisenberg's principle of
uncertain. There are also statistical proofs that some cells
may not be hit by radiation during RT. However, we con-
sider a cancer cell is so huge compare to bacteria cell, a
question here is if no-hitting cells would ever exist in RT?
To answer this, we need to know the normal exposure of
radiation among humans. The total life time exposure of
radiation of all sources is less than 0.1 Gy in average and
the virtually all cancers in atomic bomb survivors received
more than 0.1 Gy with a majority received more 1 Gy. It
Another sample figure titleFigur  4
Another sample figure title. Ratios of effective non-hit-
ting cell distributions, x-axis is tumor size and y axis is proba-
bility.
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appears 0.1 Gy dose of radiation can induce cancer, and
actually Michael Joiner et. al. [1,2] have verified the hyper
sensitivity of RT at low dose (i.e. < 0.2 Gy). This means a
low dose such as 0.1 Gy give relatively higher radio-sensi-
tivity on cell killing and is considered as a factor to induce
cancer. If a RT treatment is divided into fractionated RT
with a low dose per fraction, each fraction is typically 2 Gy
or more. Let us consider a very conservative estimation of
RT, in a case just one dose of 1 Gy, then the biological
effects on this just one time 1 Gy dose are: there are more
than 20 thousands ionization per cell, more than 100
DNA stands breaks per cell with obvious chromosome
changes and differential gene expressions and regulations.
If this 1 Gy is a high linear energy transfer radiation, 1%
of cells survive, with 30 transformations per million cells,
while if low linear energy transfer, 90% percentage of cells
survive with 3 transformations per million cells. There-
fore, it is evident that 1 Gy dose offers severe damages on
each cell, but how many cells are killed depend on
whether low or high linear energy transfer. It is obviously
not possible that there exists even one single non-hitting
cell on RT. Such non-hitting cells may possibly happen on
lower radiation dose such as 0.1 Gy or less, but definitely
not at a dose of RT. Even though the percentage of killed
cells varies from 1% to 90%, all cells are affected signifi-
cantly upon 1 Gy 0.1 Gy, humans must not have a mech-
anism to tolerate radiation of 1 Gy dose, otherwise theory
of evolution can not be valid. Upon RT, even a smallest
dose such as 1 Gy RT affects all cells and counts to the risk
of radiation induced secondary cancer. Cells that are not
killed in RT do not mean they are not hit, but they are all
damaged or at least affected somehow and may later pro-
liferate indefinitely with malignant transformation in the
offspring. Because telomerase can be damaged by radia-
tion, at the reactivation of telomerase, cells may become
immortal just like cancer cells and may undergo malig-
nant proliferation. We have measured levels of telomerase
and found telomerase is related to the malignant transfor-
mation [4,11]. Not non-hitting cells and not killed cells
should be two different concepts in RT. Upon RT, all cells
are all hit, some are damaged and some are killed. Dam-
aged cells are possibly related to tumor recurrence,
genomic instability, bystander effects, tumor malignant
transformation and metastases. Those survived tumor
cells can signal to the surrounding both normal and
tumor cells to develop blood vessels and to help re-gener-
ate killed tumor cells. Non-hitting cell models in RT are
just models based on phenomena; they should not be
interpreted as there are real non-hitting cells in RT. Joiner
et. al. [1,2] reported that radio-sensitivity is not a monot-
onic function on small doses – a phenomenon called low-
dose hyper radio-sensitivity. This has inspired us to find
that radio-sensitivity is also not monotonic function of
tumor volumes especially for microscopic diseases.
As for the genomic instability, it originally refers to
induced long lasting sub-lethal effect or normal cells turn-
ing into cancer while our view of genomic instability is the
change of gene regulation that cause abnormal differenti-
ation of original cells, that maybe related to malignant
transformation or induced apoptosis. After RT, cancer
cells can be genomic instable as well, not just normal
cells. As regard to the original bystander effect, it means
non-hitting cells die or mutate as the result of adjacent of
hitting cells on RT. Our new view of this effect is different;
there exists no possibility on even one single non-hitting
cell on RT, bystander effect maybe actually the deconstruc-
tion of tumor cellular signaling pathways.
Cancer cells do have signaling transductions
Traditional RT models do not consider cell communica-
tions. We show that Poisson-statistics based RT models
were actually based on wrongly bacterial cells of exponen-
tial growth or log cell killing on radiation without consid-
ering cellular communications. Despite that, Poisson-
statistics based RT models fit clinical data well, yet mam-
malian cells including cancer cells must maintain their
signaling transduction pathways or they cannot survive.
The large fluctuations of radio-sensitivity are resulted
from the disturbances of the signaling pathways although
they might not affect the clinical outcome of TCP. We
have shown that there is not even one non-hitting cell in
RT, then the questions is why some cells are killed, some
are not. We consider that it is also related to the cellular
signaling and communications. Back many years ago, Dr.
Tikvah Alper first proposed that damages on cell mem-
brane on RT can trigger the process of damages on cell
membrane on RT can trigger the process of apoptosis,
later Dr. Niemierko also gave biological effects of IMRT.
Therefore, a tumor cell can be killed by disturbing its sig-
naling transduction or can survive if alternative signaling
transductions can be maintained upon RT. It is not only
that human genome is abundant with splicing and alter-
native splicing, but also many proteins are multi-func-
tional [12]. It is possible alternative spliced genes can be
expressed and alternative functions of proteins can be car-
ried upon RT. At adjuvant RT, since the remaining tumor
tissues are microscopic, thus the underlying distributions
of microscopic tumor cells can vary significantly on sizes
that affect the tumor cellular communication and signal-
ing transductions.
Tumor cellular signaling transductions are also shown in
the human immune system reactions on tumor cells. The
effects are obvious on virus-induced tumors, which are
recognized by immune system immediately. A tumor cell
does communicate with outside with a cellular identifica-
tion that is depending on the glycocalices located on the
tumor cell membrane with at least a portion in the extra-
cellular space (outside the cell membrane) for immune
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cell recognitions. All four types of cell communications
have been found in tumors: endocrine signals, autocrine
signals, Paracrine signals and Juxtacrine signals. All four
types of tumor cellular communications support Nie-
mierko's theory on repairing damaged cells by un-killed
neighboring cells upon radiation [13]. Tumor cell-to-cell
communications are often made by direct contact usually
via the interaction of the glycocalices of the tumor cellular
membrane. Tumor cells are mammalian cells which are
affected by the intra-inter- and extra-cellular signaling to
receptors that face outwards from the membrane and trig-
ger the gene regulation inside cells. Therefore disturbing
the tumor cellular communications by RT can kill or affect
the survived tumor cells. GJIC (gap junction intercellular
communications) are abnormal in tumors and are not
functioning, yet there are still some signals through the
transmembrane (TM) and the ion-channels in tumor
cells.
Although almost all tumors are found to have disrupted
or abnormal GJIC, tumor cells are still mammalian cells
with cellular communications and regulations, otherwise
tumor cells can not survive. Strictly speaking, Poisson-sta-
tistics based models are incorrect biologically and that is
why Niemierko's EUD and his sequential development of
clustering algorithms [13] are so important in developing
correct RT plans. We present an equivalent uniform radio-
sensitivity model based on Niemierko's EUD. We find
that TM and intrinsically unstructured proteins (IUP) are
correlated and co-exist in cell membranes, and tend to
have opposite physiochemical prosperities [14,15]. Nie-
mierko's theory also shows that survived cell cluster can
repair the damage cells with a radius depending on the
size of the cluster.
In RT models, cancer cells are considered as immortal and
RT is aimed to achieve TCP = 100% so that a treatment
plan must achieve to kill all immortal cancer cells, other-
wise cancer will come back, even one tumor cell was not
killed. As matter of fact, cancer cells are not immortal at all
and all cancer cells must die without exception. They just
proliferate indefinitely and faster than normal cells so it
better to describe cancer cells are uncontrolled fast-grow-
ing cells. Normal cells maintain cross-linked signaling
pathway networks, which synergize health control of cell
metabolism and growth, while for cancerous cells, one of
the signaling pathways is damaged and thus result loss of
control of a signaling pathway in the networks. Cancer
cell survival is also promoted by blocking apoptosis via
the ras/phosphoinositol/Akt pathway, and such pathway
can be affected by RT. It is often unknown how radiation
alters regulatory pathways, yet it has been shown that sev-
eral types of cancer are related to co-regulations of bidirec-
tional promoters [16]. Actually it is less meaningful to
estimate how many percentage of cancer cells are killed by
RT rather it is more meaningful how malignancy and pro-
liferation get altered or controlled by RT. Because any can-
cerous cells die anyhow, the control on malignancy and
proliferation determine prognoses of patients upon RT.
Tumor cell-to-cell communications can be made through
although abnormal gap junctions, which allow different
molecules and ions to pass freely among tumor cells
throughout TM channels to keep tumor tissue well nutri-
tive Disturbing the TM signaling process can result the
death of tumor upon RT. Larger tumor tissue with a higher
spatial cell density would experience higher chances of
blocking the cell-to-cell communication upon RT because
some adjacent tumor cells had been killed, thus cell-to-
cell communication had been destroyed more severely.
Research has shown that closing gap junctions, involved
in GJIC had led to an increased cell killing by the
bystander effect. Furthermore it has been reported that
extra-cellular signaling pathways had been identified as
an integrator of multi-cellular damage responses prevent-
ing tumor development through the removal of damaged
cells and inhibition of neoplastic transformation. Larger
tumor cluster with higher density statistically experiences
a larger portion of destruction of multi-cellular communi-
cations among tumor cells thus effectively suffers larger
cell killing rate upon radiation.
Recent research showed that under appropriate micro-
environments, human breast cancer stem cells could be
induced to express their connexins and start to partially
differentiate. This gives a clue that early tumor cells may
still have telomerase activity and grow inhibition. Tumor
cells are physically contacted via their membranes, upon
RT, a larger cluster of tumor cells are killed more signifi-
cantly than complete isolated tumor cells because of more
server damages on tumor cellular communications.
Radiation can induce genetic or epigenetic change in a sin-
gle-hit cell altering the internal homeostatic control of
transcriptional regulation of the genome, thus may gener-
ating additional hits. Although this study has been con-
ducted for radiation-induced cancer [3], non-targeted and
delayed effects of exposure to ionizing radiation contrib-
ute to the death of single hit tumor cells that influence the
survival of surrounding tumor cells. There is no doubt
about the how genomic instability occurs upon radiation,
evidences have also been found in fibroblast systems of
the involvement of GJIC in bystander responses. Based on
our different definitions of bystander effect and genomic
instability given before, those evidences support our state-
ment that smaller tumor tissues receive less cell killing
rates than larger tumor tissues because of the difference of
underlying probability density distributions of tumor
cells in tumor tissues for microscopic diseases. Further-
more, tumor cells emit signals to the surrounding normal
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tissue to generate blood vessels to help tumor develop-
ment, survival of a tumor tissue also depends on its suffi-
cient blood vessels and blood circulations. Destroying
tumor blood vessels may result the death of a whole
tumor tissue. This indicates that larger tumor tissues clus-
ter should have larger cell killing rates on RT, because
blood vessels are also likely destroyed upon RT.
Finally Radio-Immuno-Therapy (RIT) built on the cyto-
toxic potential of monoclonal antibodies through the
addition of a radiation has been used successful to deliver
a therapeutic dose of radiation, involving the combina-
tion of a monoclonal antibody directed against a specific
antigen with a source of radiation. The mechanism is that
cancer cells can trigger human immune reaction while
normal cells do not. Therefore, larger cancer tissue should
trigger stronger human immune reaction. For RT, it means
a larger cell-killing rate than that of a smaller tumor tissue.
For a large microscopic tumor tissue, RT may more likely
trigger the apoptosis related pathways by more severely
disturbing tumor cellular communications, and RT works
more effectively with human immune system to achieve
larger killing effects, while for a completely isolated tumor
cell, synergy of those effects would not occur.
Conclusion
Clinical speaking, our limitation of current technology
has not enabled us to determine any amount of remaining
tumor cells after surgery [3]. Surgeons always hope that
there is not even one tumor cell remaining after removing
any visible tumor tissue. Scientifically, it is possible that
there are still invisible remaining microscopic tumor tis-
sues, but we do not have a way to verify that. The remain-
ing tumor cells can range from 1 to 108 and are not
clinically detectable. They are referred as microscopic dis-
eases by Suit and Niemierko's laboratory that reported an
offset of 12 Gy from macroscopic tumors in TCP [3]. The
possible remaining tumor cells after surgery accounts for
tumor recurrence. Adjuvant RT is often performed after
surgery and it is hard to verify the real process of cell kill-
ing in microscopic diseases. Different RT models have
been developed and many parameters had been justified
for model fittings. It has been commonly regarded that
upon RT, the larger the tumor tissue is; the less cell-killing
rate is. We find that for microscopic diseases, actually,
larger tumor tissue receives larger cell killing and radio-
sensitivity is not a monotonic function. We use the avail-
able IBTR data to calculate the cell killing rates upon RT
and show that common conclusions on cell killing can
not be extended to microscopic diseases. However, we
also demonstrate that the large fluctuations on radio-sen-
sitivity may not matter and Poisson-statistics based mod-
els can be correct clinically regardless of their wrongly
biological mechanism based on bacterial cells. RT and
human immune system can work together to kill tumor.
cells. We oppose the concept of non-hitting cells in RT
models. Our results are based an equivalent uniform
radio-sensitivity model that utilizing the concept of Nie-
mierko's EUD, we found that smaller tumor tissue may
experience less killing rate in adjuvant RT which is also
based on Niemierko's theory that un-killed surviving cell
clusters can repair/regenerate killed cells within a radius R
from each of cluster center [13]. It is commonly regarded
that tumors can be resulted from the DNA double strand
breaks and mutations; we believe that tumors are resulted
from abnormal expressions and regulations, while muta-
tions count for that. It has been widely verified that RT
break the double DNA chains and tumor cells are killed
because they can not repair the damages on the DNA
chains upon RT. We believe that the energy to break DNA
double strands for the above killing upon RT is high,
tumor cells can be killed by disturbing their intercellular
communications and the energy for that would be much
lower than breaking the DNA chains with irreparable
strength.
Tumor characteristic specific anti-genes no matter found
or not may exist and if so, may roughly proportional to
the size of tumor tissue. For some cancers, they can be
detected by patients' blood and urine tests. Based on the
clinical outcomes, if an existing tumor tissue is too tiny,
blood tests may not detect any tumor specific antigenes,
indicating that patient's immune system may not be stim-
ulated and the patient's body has not recognized the inva-
sion of a tumor yet, therefore tumor specific anti-bodies
may not have been produced yet. As tumor tissue grows
bigger, the immune system may begin to recognize the
invasion of tumor and thus may produces anti-bodies as
a result of tumor. For microscopic disease, if the remain-
ing tumor tissue after surgery is considerably large (still
invisible), patient's immune system works more effec-
tively with RT to give a larger cell killing rate than "clinical
infinitesimal" tumor tissue that the RT may work alone
without the synergy of immune system.
The aggressive biological behaviors, tumor cellular com-
munications and biological mechanism of any seed can-
cer cell or a small cluster of beginning cancerous cells
would support the finding that smaller tissues receive less
cell-killing rate on microscopic diseases. Although this
obviously contradict to some proved conclusions on RT
that large tumors are more resistant to radiotherapy due to
the higher level of hypoxia, it does mean the proved con-
clusions can not apply to tumors of microscopic diseases
(invisible tumors), because tumor cells behave differently
than simple bacterial cells. Cancer cells do communicate
each other. A killed tumor cell upon RT can trigger the
death of neighboring tumor cells and therefore, statisti-
cally, a larger tumor tissue receives larger cell-killing rate
than a tiny isolated tumor tissue, because RT significantly
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destroys large-cluster of cellular communications that
may affect genomic stability and may trigger the apoptosis
of tumor cells. This also explains that a completely iso-
lated tumor cell may experience less cell killing effect on
adjuvant RT than larger tumor tissues for microscopic dis-
eases. However as tumor tissue become larger and larger
and eventually visible, human immunize system may
begin to take significant roles, then the hypoxia effect
dominate the cell killing rate on RT. An inverse conclusion
can be reached for tumors of microscopic diseases. It can
be concluded that radio-sensitivity is not a monotonic
function on tumor size upon RT; it is proportional to the
size of tumor tissue on adjuvant RT while it decreases on
larger visible tumors.
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